780_의학강좌- 김영훈, 김경수

Similar documents
ÀÇÇа�ÁÂc00Ì»óÀÏ˘

A 617

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

hwp

Lumbar spine

03이경미(237~248)ok

페링야간뇨소책자-내지-16

DBPIA-NURIMEDIA

012임수진

975_983 특집-한규철, 정원호

00약제부봄호c03逞풚

1..

노인정신의학회보14-1호

???? 1

서론 34 2

Kor. J. Aesthet. Cosmetol., 및 자아존중감과 스트레스와도 밀접한 관계가 있고, 만족 정도 에 따라 전반적인 생활에도 영향을 미치므로 신체는 갈수록 개 인적, 사회적 차원에서 중요해지고 있다(안희진, 2010). 따라서 외모만족도는 개인의 신체는 타

(

<30352EC6AFC1FD2DC0CCC1BEB8ED2E687770>

YI Ggodme : The Lives and Diseases of Females during the Latter Half of the Joseon Dynasty as Reconstructed with Cases in Yeoksi Manpil (Stray Notes w

¼Û±âÇõ

The Window of Multiple Sclerosis

878 Yu Kim, Dongjae Kim 지막 용량수준까지도 멈춤 규칙이 만족되지 않아 시행이 종료되지 않는 경우에는 MTD의 추정이 불가 능하다는 단점이 있다. 최근 이 SM방법의 단점을 보완하기 위해 O Quigley 등 (1990)이 제안한 CRM(Continu

The clinical experience of anti-IgE antibody treatment in patients with refractory chronic urticaria

<30312DC1A4BAB8C5EBBDC5C7E0C1A4B9D7C1A4C3A52DC1A4BFB5C3B62E687770>

Ⅰ. 서 론 鼻 茸 은 비강과 부비동의 점막이 염증성, 부종성 변 화로 돌출되어 발생하는 질환으로 비교적 흔하며 그 표면이 매끄럽고 회백색 혹은 회적색을 띠고 있다. 감 염과 알레르기가 중요한 발병원인으로 생각되고 있으 며, 치료 후에도 잘 재발하는 만성 염증성 질환이

Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

7.ƯÁýb71ÎÀ¯È« š


Treatment and Role of Hormaonal Replaement Therapy

untitled

한국성인에서초기황반변성질환과 연관된위험요인연구


< D B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A E687770>

139~144 ¿À°ø¾àħ

untitled

( )Jkstro011.hwp


< FC1F8B9E6B1B3C0B02E687770>

°ø±â¾Ð±â±â

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

김범수

J Korean Med Assoc 2017 February; 60(2): Received: November 27, 2016 Accepted: January 10, 2017 *These two authors contributed equally to this

online ML Comm Clinical Review Korean J Otorhinolaryngol-Head Neck Surg 2013;56: / pissn / eissn

歯1.PDF


WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disabi

Rheu-suppl hwp

석사논문.PDF


Journal of Educational Innovation Research 2018, Vol. 28, No. 1, pp DOI: * A Analysis of

232 도시행정학보 제25집 제4호 I. 서 론 1. 연구의 배경 및 목적 사회가 다원화될수록 다양성과 복합성의 요소는 증가하게 된다. 도시의 발달은 사회의 다원 화와 밀접하게 관련되어 있기 때문에 현대화된 도시는 경제, 사회, 정치 등이 복합적으로 연 계되어 있어 특

레이아웃 1

歯5-2-13(전미희외).PDF


Journal of Educational Innovation Research 2017, Vol. 27, No. 1, pp DOI: * The

433대지05박창용

충북의대학술지 Chungbuk Med. J. Vol. 27. No. 1. 1~ Charcot-Marie-Tooth Disease 환자의마취 : 증례보고 신일동 1, 이진희 1, 박상희 1,2 * 책임저자 : 박상희, 충북청주시서원구충대로 1 번지, 충북대학교

DBPIA-NURIMEDIA

황지웅

기관고유연구사업결과보고

44-4대지.07이영희532~


16(2)-7(p ).fm

12이문규

DBPIA-NURIMEDIA

<30382EC0C7C7D0B0ADC1C22E687770>

( ) ) ( )3) ( ) ( ) ( ) 4) 1915 ( ) ( ) ) 3) 4) 285

Journal of Educational Innovation Research 2019, Vol. 29, No. 2, pp DOI: 3 * Effects of 9th

141(26) () ( ( ) () () () ) 2) 1932 ()()3) 2 1) ( ) ( ) () () () 4) ( ) 5) 6) ) ) ( ) () 42 () )

03-ÀÌÁ¦Çö

KIM Sook Young : Lee Jungsook, a Korean Independence Activist and a Nurse during the 이며 나름 의식이 깨어있던 지식인들이라 할 수 있을 것이다. 교육을 받은 간 호부들은 환자를 돌보는 그들의 직업적 소

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re

04_이근원_21~27.hwp

DBPIA-NURIMEDIA

Trd022.hwp

hapter_ i i 8 // // 8 8 J i 9K i? 9 i > A i A i 8 8 KW i i i W hapter_ a x y x y x y a /()/()=[W] b a b // // // x x L A r L A A L L A G // // // // /

27 2, 1-16, * **,,,,. KS,,,., PC,.,,.,,. :,,, : 2009/08/12 : 2009/09/03 : 2009/09/30 * ** ( :

(JH)

untitled

???? 1

:,,.,. 456, 253 ( 89, 164 ), 203 ( 44, 159 ). Cronbach α= ,.,,..,,,.,. :,, ( )

<5B31362E30332E31315D20C5EBC7D5B0C7B0ADC1F5C1F8BBE7BEF720BEC8B3BB2DB1DDBFAC2E687770>

Journal of Educational Innovation Research 2018, Vol. 28, No. 4, pp DOI: * A Research Trend

공학박사학위 논문 운영 중 터널확대 굴착시 지반거동 특성분석 및 프로텍터 설계 Ground Behavior Analysis and Protector Design during the Enlargement of a Tunnel in Operation 2011년 2월 인하대

<3136C1FD31C8A35FC3D6BCBAC8A3BFDC5F706466BAAFC8AFBFE4C3BB2E687770>

Journal of Educational Innovation Research 2016, Vol. 26, No. 2, pp DOI: * Experiences of Af

( )Kju269.hwp

Analysis of objective and error source of ski technical championship Jin Su Seok 1, Seoung ki Kang 1 *, Jae Hyung Lee 1, & Won Il Son 2 1 yong in Univ

ePapyrus PDF Document

16(1)-3(국문)(p.40-45).fm

DBPIA-NURIMEDIA

09구자용(489~500)


<30312DC1A4BAB8C5EBBDC5C7E0C1A4B9D7C1A4C3A528B1E8C1BEB9E8292E687770>


<BAF1B8B8C3DFB0E8C7D0BCFAB9D7BFACBCF62D E E687770>

Kor. J. Aesthet. Cosmetol., 라이프스타일은 개인 생활에 있어 심리적 문화적 사회적 모든 측면의 생활방식과 차이 전체를 말한다. 이러한 라이프스 타일은 사람의 내재된 가치관이나 욕구, 행동 변화를 파악하여 소비행동과 심리를 추측할 수 있고, 개인의

A 001~A 036

노영남

Transcription:

Continuing Education Column DOI: 10.5124/jkma.2010.53.9.780 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Diagnosis and treatment of allergic rhinitis Young Hoon Kim, MDKyung-Su Kim, MD Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea * Corresponding author: Kyung-Su Kim, E-mail: ydrhinol@yuhs.ac Received July 7, 2010 Accepted July 21, 2010 Abstract Allergic rhinitis (AR) is a global health problem affecting at least 10 to 25% of the population, and is a chronic respiratory illness that affects quality of life, productivity, and other co-morbid conditions such as asthma and sinusitis. Classification of AR has been changed to intermittent/persistent (duration) and mild/moderate-severe (severity) based on the Allergic Rhinitis and Its Impact on Asthma (ARIA) workshop report published in 2001. A patient's history and skin prick test results are of utmost importance for its diagnosis regardless of classification system. Treatment should be based on the patient's age, severity, and duration of symptoms. The treatment algorithm has recently been revised by 2008 ARIA guidelines. Treatment options for AR consist of allergen avoidance, pharmacotherapy, immunotherapy, and surgery. Patients should be advised to avoid known allergens and educate themselves about their condition. Although allergen avoidance and immunotherapy are theoretically ideal, intranasal corticosteroids are the most effective treatment in persistent and moderate-severe AR. Sublingual immunotherapy has been introduced and has shown good results in its efficacy and safety. Physicians are advised to be alert to the state-of-the-art knowledge on AR and be willing to take advantage of recent progress on AR. Keywords: Allergic rhinitis; Skin test; Immunotherapy c Korean Medical Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 780

Diagnosis and treatment of allergic rhinitis Intermittent symptoms <4 days per week or <4 consecutive weeks Persistent symptoms >4 days/week and >4 consecutive weeks Mild all of the following normal sleep no impairment of daily activities, sport, leisure no impairment of work and school symptoms present but not troublesome Figure 1. ARIA classification of severity of allergic rhinitis[4]. Moderate-severe one of more items sleep disturbance impairment of daily activities, sport, leissure impairment of school or work troublesome symptoms 781

Kim YHKim KS 782

Diagnosis and treatment of allergic rhinitis Table 1. Differential diagnosis of rhinitis Allergic rhinitis Nonallergic rhinitis (continued) Conditions that may mimic symptoms of rhinitis Episodic rhinitis Gustatory rhinitis Cerebrospinal fluid rhinorrhea Occupational rhinitis Hormone-induced rhinitis Inflammatory or immunologic conditions (allergen) Hypothyroidism Midine granuloma Perennial rhinitis Menstrual cycle Nasal polyposis Seasonal rhinitis Oral contraceptives Sarcoidosis Nonallergic rhinitis Pregnancy Sjogrens syndrome Atrophic rhinitis Infectious rhinitis Systemic lupus erythematosus Chemical-or irritant-induced rhinitis Acute (usually viral) Wegeners granulomatosis Drug-induced rhinitis Chronic rhinosinusitis Relapsing polychondritis Antihypertensive medications Nonallergic rhinitis with eosinophilia Structural or mechanical conditions Nonsteroidal anti-inflammatory drugs syndrome Choanal atresia Oral contraceptives Occupational rhinitis (irritant) Deviated septum Rhinitis medicamentosa Perennial nonallergic rhinitis Enlarged adenoids Emotional rhinitis Vasomotor rhinitis Foreingn bodies Exercise-indued rhinitis Postural reflexes Hypertrophic turbinates Primary ciliary dyskinesia Nasal tumors Reflux-induced rhinitis or gastroesophageal reflux disease 783

Kim YHKim KS Table 2. Allergic vs. Non-allergic rhinitis Clinical characteristic Allergic rhinitis Non-allergic rhinitis Ancillary studies Positive skin tests Negative skin tests Exacerbating factors Allergen exposure Irritant exposure, weather changes Family history of allergies Usually present Usually absent Nasal eosinophilla Nature of symptoms Usually present Present in patients with nonallergic rhinitis with eosinophilia syndrome Congestion Common Common Postnasal drip Not prominent Prominent Pruritus Common Rare Rhinorrhea Sneezing Common Prominent Usually uncommon, but may be present in some patients Usually not prominent, but may predominate in some patients Other allergic symptoms Often present Absent Physical appearance of nasal mucosa Seasonality Variable, described as pale, boggy, and Swollen Seasonal variation Variable, erythematous Usually perennial, but symptoms may Worsen during weather changes. 784

Diagnosis and treatment of allergic rhinitis Diagnosis of allergic rhinitis Check for asthma especially in patients with severe and/or persistent rhinitis Intermittent symptoms Persistent symptoms Mild Moderate-severe Mild Moderate-severe Not in preferred order oral H1 blocker or intranasal H1-blocker and/or decongestantor LTRA Not in preferred order oral H1 blocker or intranasal H1-blocker and/or decongestant or Intranasal CS or LTRA (or cromone) In persistent rhinitis review the patient after 2-4 weeks If faliure: step-up If improved: continue for 1 month Improved Step-down and continue treatment for >1 month Add or increase intranasal CS dose In preferred order Intranasal CS H1 blocker or LTRA Review the patient after 2-4 weeks Rhinorrhea add ipratroplum Failure Review diagnosis Review compliance Query infections or other causes Blockage add decongestant or oral CS (short term) Failure referral to specialist Figure 2. ARIA algorithm for treatment of allergic rhinitis[20]. Allergen and irritant avoidance may be appropriate If conjunctivitis Add oral H1-blocker or intraocular H1-blocker or intraocular cromone (or saline) Consider specific immunotherapy 785

Kim YHKim KS 786

Diagnosis and treatment of allergic rhinitis 787

Kim YHKim KS REFERENCES 11. Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948-953. 12. Jee HM, Kim KW, Kim CS, Sohn MH, Shin DC, Kim KE. Prevalence of asthma, rhinitis, and eczema in Korean children using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaires. Pediatr Allergy Respir Dis (Korea) 2009; 19: 165-172. 13. Bjorksten B, Clayton T, Stewart A, Strachan D. Worldwild time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008; 19: 110-124. 14. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 Suppl): S147-334. 15. Salib RJ, Lau LC, Howarth PH. The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clin Exp Allergy 2005; 35: 811-819. 16. Hamilton RG. Clinical laboratory assessment of immediatetype hypersensitivity. J Allergy Clin Immunol. 2010; 125: S284-296. 17. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010; 2: 65-76. 18. Jung YG, Cho HJ, Park GY, Min JY, Kim HY, Dhong HJ, Chung SK, Kim SW. Comparison of the skin-prick test and Phadia ImmunoCAP as tools to diagnose house-dust mite allergy. Am J Rhinol Allergy 2010; 24: 226-229. 19. Bang JH, Kim YJ, Shin HS, Lee BJ. Clinical analysis of allergic rhinitis in Seoul. J Rhinol 1996; 3: 130-134. 10. Heo Y, Kim HA. Correlation between skin prick test and enzyme-linked immunosorbent assay using serum for identification of subjects positive to major indoor respiratory allergen. J Env Health Sci 2008; 34: 369-373. 11. Larenas-Linnemann D, Matta JJ, Shah-Hosseini K, Michels A, Mösges R. Skin prick test evaluation of Dermatophagoides pteronyssinus diagnostic extracts from Europe, Mexico, and the United States. Ann Allergy Asthma Immunol 2010; 104: 420-425. 12. Nelson HS. Diagnostic procedures in allergy. I. allergy skin testing. Ann Allergy 1983; 51: 411-418. 13. Jang TY, Choi JC, Jung DH. Detection of Specific IgE Antibody from Nasal Secretion in Allergic Rhinitis. Korean J Otolaryngol 2000; 43: 1318-1322. 14. Han MY, Jee JM, Kim HY, Lee CA, Cho HJ, Hwang SG, Kim KE. Toll-like receptor 9 expression and interferon-secretion upon CpG-ODN stimulation in allergic subjects. Korean J Pediatr 2009; 52: 1015-1020. 15. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy 2003; 58: 691-706. 16. Emanuel IA, Shah SB. Chronic rhinosinusitis: allergy and sinus computed tomography relationships. Otolaryngol Head Neck Surg 2000; 123: 687-691. 17. Nguyen LH, Manoukian JJ, Sobol SE, Tewfik TL, Mazer BD, Schloss MD, Taha R, Hamid QA. Similar allergic inflammation in the middle ear and upper airway: evidence linking otitis media with effusion to the united airway concept. J Allergy Clin Immunol 2004; 114: 1110-1115. 18. Ng TP, Tan WC. Epidemiology of allergic rhinitis and its associated risk factors in Singapore. Int J Epidemiol 1994; 23: 553-558. 19. Rha YH. Allergic rhinitis in children: diagnosis and treatment. Korean J Pediatr 2006; 49: 593-601. 20. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, 788

Diagnosis and treatment of allergic rhinitis Togias A, Zuberbier T, Baena-Cagnani CE, Canoncia GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, OHeir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wicjman M, Yawn BP, Yorgandipglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chang-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas- Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, William D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63: 8-160. 21. Moscato G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, Quirce S, Walusiak J, Castano R, Pala G, Gautrin D, De Groot H, Folletti I, Yacoub MR, Siracusa A; European Academy of Allergology and Clinical Immunology. EAACI position paper on occupational rhinitis. Respir Res 2009; 10: 16. 22. Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010; 81: 1440-1446. 23. Simons FER. H1-receptor antagonist: safety issues. Ann Allergy Asthma Immunol 1999; 83: 481-488. 24. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 2003; 63: 1813-1820. 25. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003; 91: 205-211. 26. Miadonna A, Tedeschi A, Leggieri E, Lorini M, Folco G, Sala A, Qualizza R, Froldi M, Zanussi C. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136: 357-362. 27. Kurowski M, Kuna P, Gorski P. Montelukast plus cetrizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004; 59: 280-288. 28. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 2000; 161: S133-S136. 29. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987; 316: 1506-1510. 30. Pipkorn U. Effect of topical glucocorticoid treatment on nasal mucosal mast cells in allergic rhinitis. Allergy 1983; 38: 125-129. 31. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vanderwalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B. Absence of growth retardation in children with pereneal allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: E22. 32. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407-413. 33. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91: 97-101. 34. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 2001; 87: 38-42. 35. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, Jolles SR, Siddique N, Cullinan P, Howarth PH, Nasser SM; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38: 19-42. 36. Frew AJ. Sublingual immunotherapy. N Engl J Med 2008; 358: 2259-2264. 37. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, Canoncia GW. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patient 3 to 18 years of age: meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97: 141-148. 38. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10 year prospective study. Clin Exp Allergy 2003; 33: 206-210. 39. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035. 40. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandstorm T, Rak S. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110: 68-71. 41. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28: 313-319. 789

Kim YHKim KS Peer Reviewers Commentary 790